[시장보고서]세계의 경구용 고형제 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

세계의 경구용 고형제 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Oral Solid Dosage Pharmaceutical Formulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1552663

리서치사 : Transparency Market Research

발행일 : 2024년 07월

페이지 정보 : 영문 167 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,478,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,867,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,256,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

경구용 고형제 시장 - 조사 범위

TMR의 조사 보고서 "세계 경구용 고형제 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준 연도, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 경구용 고형제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 경구용 고형제 시장의 연평균 성장률(CAGR%)도 제시합니다.

이 보고서는 광범위한 1차 조사, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 경구용 고형제 시장을 추론했습니다, 경구용 고형제 시장을 추론했습니다.

시장 현황
2023년 시장 규모	6억 5,460만 달러
2034년 시장 규모	11억 달러
CAGR	5.2%

이 보고서는 세계 경구용 고형제 시장의 경쟁 환경을 조사했습니다. 세계 경구용 고형제 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등 세계 경구용 고형제 시장 기업의 속성은 이 보고서에서 다루고 있습니다.

서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 제형별, 2020-2034년
- 정제
  - 기존/즉시 방출
  - 조절 방출
  - 츄어블자물쇠
  - 발포자물쇠
- 캡슐
  - 하드 젤라틴 캡슐
  - 소프트젤라틴 캡슐
- 분말
- 로젠지·트로키
- 그미
시장의 매력 분석 : 제형별

제7장 세계 시장 분석과 예측 : 약물 방출 메커니즘별

서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 약물 방출 메커니즘별, 2020-2034년
- 즉시 방출
- 지연 방출
- 제어 방출
시장의 매력 분석 : 약물 방출 메커니즘별

제8장 세계 시장 분석과 예측 : 유통 채널별

서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 유통 채널별, 2020-2034년
- 병원 약국
- 소매 약국
- 온라인 약국
시장의 매력 분석 : 유통 채널별

제9장 세계 시장 분석과 예측 : 지역별

주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
시장의 매력 분석 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 구도

시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Biogen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Takeda Pharmaceutical Company
- Otsuka Pharmaceutical Co., Ltd.

LSH

영문 목차

영문목차

Oral Solid Dosage Pharmaceutical Formulation Market - Scope of Report

TMR's report on the global oral solid dosage pharmaceutical formulation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global oral solid dosage pharmaceutical formulation market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oral solid dosage pharmaceutical formulation market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the oral solid dosage pharmaceutical formulation market.

Market Snapshot
Market Value in 2023	US$ 654.6 Mn
Market Value in 2034	US$ 1.1 Bn
CAGR	5.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oral solid dosage pharmaceutical formulation market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oral solid dosage pharmaceutical formulation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oral solid dosage pharmaceutical formulation market.

The report delves into the competitive landscape of the global oral solid dosage pharmaceutical formulation market. Key players operating in the global oral solid dosage pharmaceutical formulation market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oral solid dosage pharmaceutical formulation market profiled in this report.

Key Questions Answered in Global oral solid dosage pharmaceutical formulation Market Report:

What is the sales/revenue generated by oral solid dosage pharmaceutical formulation across all regions during the forecast period?
What are the opportunities in the global oral solid dosage pharmaceutical formulation market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Oral Solid Dosage Pharmaceutical Formulation Market - Research Objectives and Research Approach

The comprehensive report on the global oral solid dosage pharmaceutical formulation market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oral solid dosage pharmaceutical formulation market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oral solid dosage pharmaceutical formulation market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Oral Solid Dosage Pharmaceutical Formulation Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, 2020-2034

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Dosage Form

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Dosage Form, 2020-2034
- 6.3.1. Tablets
  - 6.3.1.1. Conventional/Immediate Release
  - 6.3.1.2. Modified Release
  - 6.3.1.3. Chewable Tablets
  - 6.3.1.4. Effervescent Tablets
- 6.3.2. Capsules
  - 6.3.2.1. Hard Gelatin Capsules
  - 6.3.2.2. Soft Gelatin Capsules
- 6.3.3. Powders
- 6.3.4. Lozenges & Pastilles
- 6.3.5. Gummies
6.4. Market Attractiveness Analysis, by Dosage Form

7. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Drug Release Mechanism

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Release Mechanism, 2020-2034
- 7.3.1. Immediate Release
- 7.3.2. Delayed Release
- 7.3.3. Controlled Release
7.4. Market Attractiveness Analysis, by Drug Release Mechanism

8. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Dosage Form, 2020-2034
- 10.3.1. Tablets
  - 10.3.1.1. Conventional/Immediate Release
  - 10.3.1.2. Modified Release
  - 10.3.1.3. Chewable Tablets
  - 10.3.1.4. Effervescent Tablets
- 10.3.2. Capsules
  - 10.3.2.1. Hard Gelatin Capsules
  - 10.3.2.2. Soft Gelatin Capsules
- 10.3.3. Powders
- 10.3.4. Lozenges & Pastilles
- 10.3.5. Gummies
10.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
- 10.4.1. Immediate Release
- 10.4.2. Delayed Release
- 10.4.3. Controlled Release
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
- 10.6.1. U.S.
- 10.6.2. Canada
10.7. Market Attractiveness Analysis
- 10.7.1. By Dosage Form
- 10.7.2. By Drug Release Mechanism
- 10.7.3. By Distribution Channel
- 10.7.4. By Country

11. Europe Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Dosage Form, 2020-2034
- 11.3.1. Tablets
  - 11.3.1.1. Conventional/Immediate Release
  - 11.3.1.2. Modified Release
  - 11.3.1.3. Chewable Tablets
  - 11.3.1.4. Effervescent Tablets
- 11.3.2. Capsules
  - 11.3.2.1. Hard Gelatin Capsules
  - 11.3.2.2. Soft Gelatin Capsules
- 11.3.3. Powders
- 11.3.4. Lozenges & Pastilles
- 11.3.5. Gummies
11.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
- 11.4.1. Immediate Release
- 11.4.2. Delayed Release
- 11.4.3. Controlled Release
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
- 11.7.1. By Dosage Form
- 11.7.2. By Drug Release Mechanism
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region

12. Asia Pacific Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Dosage Form, 2020-2034
- 12.3.1. Tablets
  - 12.3.1.1. Conventional/Immediate Release
  - 12.3.1.2. Modified Release
  - 12.3.1.3. Chewable Tablets
  - 12.3.1.4. Effervescent Tablets
- 12.3.2. Capsules
  - 12.3.2.1. Hard Gelatin Capsules
  - 12.3.2.2. Soft Gelatin Capsules
- 12.3.3. Powders
- 12.3.4. Lozenges & Pastilles
- 12.3.5. Gummies
12.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
- 12.4.1. Immediate Release
- 12.4.2. Delayed Release
- 12.4.3. Controlled Release
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
- 12.7.1. By Dosage Form
- 12.7.2. By Drug Release Mechanism
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region

13. Latin America Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Dosage Form, 2020-2034
- 13.3.1. Tablets
  - 13.3.1.1. Conventional/Immediate Release
  - 13.3.1.2. Modified Release
  - 13.3.1.3. Chewable Tablets
  - 13.3.1.4. Effervescent Tablets
- 13.3.2. Capsules
  - 13.3.2.1. Hard Gelatin Capsules
  - 13.3.2.2. Soft Gelatin Capsules
- 13.3.3. Powders
- 13.3.4. Lozenges & Pastilles
- 13.3.5. Gummies
13.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
- 13.4.1. Immediate Release
- 13.4.2. Delayed Release
- 13.4.3. Controlled Release
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 13.5.1. Hospital Pharmacies
- 13.5.2. Retail Pharmacies
- 13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
- 13.7.1. By Dosage Form
- 13.7.2. By Drug Release Mechanism
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region

14. Middle East & Africa Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast

14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Dosage Form, 2020-2034
- 14.3.1. Tablets
  - 14.3.1.1. Conventional/Immediate Release
  - 14.3.1.2. Modified Release
  - 14.3.1.3. Chewable Tablets
  - 14.3.1.4. Effervescent Tablets
- 14.3.2. Capsules
  - 14.3.2.1. Hard Gelatin Capsules
  - 14.3.2.2. Soft Gelatin Capsules
- 14.3.3. Powders
- 14.3.4. Lozenges & Pastilles
- 14.3.5. Gummies
14.4. Market Value Forecast, by Drug Release Mechanism, 2020-2034
- 14.4.1. Immediate Release
- 14.4.2. Delayed Release
- 14.4.3. Controlled Release
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
- 14.5.1. Hospital Pharmacies
- 14.5.2. Retail Pharmacies
- 14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
- 14.7.1. By Dosage Form
- 14.7.2. By Drug Release Mechanism
- 14.7.3. By Distribution Channel
- 14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
- 15.3.1. AstraZeneca plc
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Financial Overview
  - 15.3.1.5. Strategic Overview
- 15.3.2. Bristol-Myers Squibb Company
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Financial Overview
  - 15.3.2.5. Strategic Overview
- 15.3.3. Eli Lilly and Company
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Financial Overview
  - 15.3.3.5. Strategic Overview
- 15.3.4. Gilead Sciences, Inc.
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Financial Overview
  - 15.3.4.5. Strategic Overview
- 15.3.5. Merck & Co. Inc.
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Financial Overview
  - 15.3.5.5. Strategic Overview
- 15.3.6. Novartis AG
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Financial Overview
  - 15.3.6.5. Strategic Overview
- 15.3.7. Pfizer Inc.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Financial Overview
  - 15.3.7.5. Strategic Overview
- 15.3.8. AbbVie Inc.
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Financial Overview
  - 15.3.8.5. Strategic Overview
- 15.3.9. Boehringer Ingelheim GmbH
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Financial Overview
  - 15.3.9.5. Strategic Overview
- 15.3.10. F. Hoffmann-La Roche Ltd.
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. SWOT Analysis
  - 15.3.10.4. Financial Overview
  - 15.3.10.5. Strategic Overview
- 15.3.11. Johnson & Johnson
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Product Portfolio
  - 15.3.11.3. SWOT Analysis
  - 15.3.11.4. Financial Overview
  - 15.3.11.5. Strategic Overview
- 15.3.12. Biogen Inc.
  - 15.3.12.1. Company Overview
  - 15.3.12.2. Product Portfolio
  - 15.3.12.3. SWOT Analysis
  - 15.3.12.4. Financial Overview
  - 15.3.12.5. Strategic Overview
- 15.3.13. Bayer AG
  - 15.3.13.1. Company Overview
  - 15.3.13.2. Product Portfolio
  - 15.3.13.3. SWOT Analysis
  - 15.3.13.4. Financial Overview
  - 15.3.13.5. Strategic Overview
- 15.3.14. Teva Pharmaceutical Industries Ltd.
  - 15.3.14.1. Company Overview
  - 15.3.14.2. Product Portfolio
  - 15.3.14.3. SWOT Analysis
  - 15.3.14.4. Financial Overview
  - 15.3.14.5. Strategic Overview
- 15.3.15. Amgen Inc.
  - 15.3.15.1. Company Overview
  - 15.3.15.2. Product Portfolio
  - 15.3.15.3. SWOT Analysis
  - 15.3.15.4. Financial Overview
  - 15.3.15.5. Strategic Overview
- 15.3.16. Takeda Pharmaceutical Company
  - 15.3.16.1. Company Overview
  - 15.3.16.2. Product Portfolio
  - 15.3.16.3. SWOT Analysis
  - 15.3.16.4. Financial Overview
  - 15.3.16.5. Strategic Overview
- 15.3.17. Otsuka Pharmaceutical Co., Ltd.
  - 15.3.17.1. Company Overview
  - 15.3.17.2. Product Portfolio
  - 15.3.17.3. SWOT Analysis
  - 15.3.17.4. Financial Overview
  - 15.3.17.5. Strategic Overview